PhotoCure ASA

Discover Photocure ASA: Norway’s pharma leader behind Hexvix, Cevira and Visonac, its market outlook, stock insights, and future growth potential.

Photocure ASA tops Q4 2025 with strong Hexvix/Cysview growth, expanding U.S. blue‑light cystoscopy, and bullish 2026 revenue outlook.

PhotoCure ASA, a Norwegian pharmaceutical company founded in 1997, has established itself as a leader in the development and distribution of innovative products for niche markets, including bladder cancer detection and acne treatment, despite facing…

Photocure ASA reported strong Q2 2025 performance, with Hexvix/Cysview revenues reaching an all-time high of NOK 135.6 million, despite a decrease in EBITDA.